SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether certain officers and directors of Prosensa Holding N.V. (NASDAQ: RNA) violated state or federal laws. Prosensa is a Dutch biotechnology company engaged in the discovery and development of ribonucleic acid-modulating therapeutics for the treatment of genetic disorders.

On September 20, 2013 Prosensa stock plummeted 70% after the Company disclosed that its experimental muscular dystrophy drug failed to meet set goals in a late-stage study. Prosensa is developing this drug, drisapersen, with GlaxoSmithKline to treat Duchenne muscular dystrophy. The study cited that the main goal of generating a statistical improvement in walking was not met.

The stock closed on February 4, 2013 at $6.13, down from the June 2013 opening initial public offering price of $20.00.

Johnson & Weaver’s investigation will seek to determine if investors were previously misled by Prosensa’s officers or directors concerning drisapersen’s potential.

If you have information that could assist in this investigation, or if you are a Prosensa shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (jimb@johnsonandweaver.com) by email or by phone at 619-230-0063, Ext. 118.

Johnson & Weaver, LLP is a nationally recognized shareholders’ rights law firm. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.